Tissue homeostasis requires a carefully-orchestrated balance between cell proliferation, cellular senescence and cell death. Cells proliferate through a cell cycle that is tightly regulated by cyclin-dependent kinase activities. Cellular senescence is a safeguard program limiting the proliferative competence of cells in living organisms. Apoptosis eliminates unwanted cells by the coordinated activity of gene products that regulate and effect cell death. The intimate link between the cell cycle, cellular senescence, apoptosis regulation, cancer development and tumor responses to cancer treatment has become eminently apparent. Extensive research on tumor suppressor genes, oncogenes, the cell cycle and apoptosis regulatory genes has revealed how the DNA damage-sensing and -signaling pathways, referred to as the DNA-damage response network, are tied to cell proliferation, cell-cycle arrest, cellular senescence and apoptosis. DNA-damage responses are complex, involving "sensor" proteins that sense the damage, and transmit signals to "transducer" proteins, which, in turn, convey the signals to numerous "effector" proteins implicated in specific cellular pathways, including DNA repair mechanisms, cell-cycle checkpoints, cellular senescence and apoptosis. The Bcl-2 family of proteins stands among the most crucial regulators of apoptosis and performs vital functions in deciding whether a cell will live or die after cancer chemotherapy and irradiation. In addition, several studies have now revealed that members of the Bcl-2 family also interface with the cell cycle, DNA repair/recombination and cellular senescence, effects that are generally distinct from their function in apoptosis. In this review, we report progress in understanding the molecular networks that regulate cell-cycle checkpoints, cellular senescence and apoptosis after DNA damage, and discuss the influence of some Bcl-2 family members on cell-cycle checkpoint regulation.
INTRODUCTION
The DNA-damage response network is highly complex and involves a multitude of proteins that sense the damage, transduce signals into cells and execute cellular responses. DNA double-strand break "sensor" proteins constitute NBS1/Mre11/Rad50 multiprotein complexes recruited at DNA damage sites, where they create rapidly-expanding nuclear foci referred to as DNA damage heterochromatin foci, with phosphorylated histone γ-H2AX and other proteins, including BRCA1, 53BP1 and MDC1. The "transducer" protein of DNA double-strand breaks is the phosphoinositide 3-kinase-related kinase ATM, which, in turn, activates multiple "effector" proteins, including p53, Mdm2, and CHK2. DNA-PK, another phosphoinositide 3-kinase-related kinase recruited at DNA damage heterochromatin foci, is involved in the non-homologous end-joining repair pathway, whereas Rad51 is implicated in DNA recombination repair pathways. Although less well-characterized, DNA replication fork stalling and DNA single-strand break alarms include ATR, ATRIP, RPA, Rad9/Rad1/Hus1, Rad17/RSR and claspin. ATR, a phosphoinositide 3-kinase-related kinase, in turn, activates multiple "effector" proteins, including p53 and CHK1 (reviewed in Bakkenist and Kastan, 2004; Shiloh, 2006) . Activation of these "effector" proteins influences cell-cycle progression and arrest, cellular senescence and apoptosis activation.
CELL-CYCLE CHECKPOINT REGULATION
Timely progression through the cell division cycle ensures the correct transmission of genetic information from a cell to its daughters. Once stimulated in proper environment with suitable growth factors, quiescent cells leave a resting phase of the cell cycle, called gap 0 (G0), and enter the gap 1 (G1) phase, prior to the DNA replication or synthesis (S) phase, followed by a second gap (G2) phase, and cell division or mitosis (M). Cell-cycle checkpoints maintain the order and fidelity of cell-cycle events in response to replicative stress and DNA strand breaks (Nigg, 2001) . The molecular mechanisms associated with these cell-cycle checkpoints entail the transient inactivation of a series of specific cyclin-dependent kinases (cdks) and their respective regulatory cyclin subunits. During normal phase progression and at key cell-cycle transition phases, specific cdk-cyclin complexes are activated by dephosphorylation, mediated by the dual specificity cdc25 phosphatase family, including cdc25A, -B and -C. The cdk-cyclin complexes influencing G1 progression and G1/S cell-cycle checkpoint are primarily cdk4-cyclinD, cdk6-cyclinD and cdk2-cyclinE (Koff et al., 1992; Sherr and Roberts, 1995) . In response to DNA damage, ATM/ATR protein kinases activate the checkpoint serine/threonine kinases, CHK1 and CHK2. To prevent entry into S phase, CHK1 and CHK2 target the cell-cycle regulatory phosphatase cdc25A. Phosphorylation of cdc25A on several residues, including Ser123, leads to its ubiquitin-mediated proteolysis, and to sustained phosphorylation and inhibition of cdk2-cyclinE complexes, that normally promote G1/S transition (Falck et al., 2001) . Several small proteins, the cdk-cyclin inhibitors (cdkIs), which bind to and inhibit cdk-cyclin activities, also play critical role in the G1/S cell-cycle checkpoint. The most potent cdkIs are p21, p27 and p57 for cdk2-cyclinE, and p16 for cdk4-cyclinD or cdk6-cyclinD (Sherr and Roberts, 1995) . Activation of these cdkIs causes G1/S cell-cycle arrest after DNA damage (Kohn et al., 1994; Hunter and Pines, 1994; Kastan et al., 1995; Kohn, 1996; Kaufmann and Paules, 1996; Jacks, 1996; Tanaka et al., 1996) . Indeed, ATM/ATR and CHK1/CHK2 kinases also target p53. In turn, p53 phosphorylation and stabilization by ATM/ATR and CHK1/CHK2 lead to accumulation of the cdkI p21, which is involved in more sustained G1/S cell-cycle arrest (Shiloh, 2001) .
Progression into the S phase and transition from G2 into M are regulated by the serine-threonine cdk2 and cdk1 (cdc2), respectively. Activation of cdk2 and cdk1 (cdc2) requires the association of their positive subunits, cyclinA and cyclinB, respectively, and the phosphorylation of Thr161 by cdk-activating kinase. These cdk-cyclin complexes are also negatively regulated by phosphorylation at Thr14 and Tyr15, which are catalyzed by inhibitory protein kinases, including Wee1, Myt1 and Mik1 (Nigg, 2001; Draetta and Beach, 1988; Draetta et al., 1989; Riabowol et al., 1989; Ducommun et al., 1991; King et al., 1994; Labib et al., 1995; McGowan and Russell, 1995; Mueller et al., 1995; Liu et al., 1997; O'Connell et al., 1997; Booher et al., 1997) . During S phase progression and at G2/M phase transition, dephosphorylation of Thr14 and Tyr15 by the cdc25 protein phosphatase cdc25A, -B, and -C, triggers cdk2-cyclinA (intra-S phase) and cdk1 (cdc2)-cyclinB (at G2/M) activation. During the DNA-damage response, activation of ATM/ATR and the downstream checkpoint kinases CHK1/CHK2 leads to the phosphorylation of all 3 cdc25 phosphatases, which creates binding sites for 14-3-3 proteins and sequestration of the phosphatases away from cdk2-cyclinA and cdk1 (cdc2)-cyclinB (Borgne and Meijer, 1996; Peng et al., 1997; Zeng et al., 1998; Sanchez et al., 1997; Matsuoka et al., 1998; Brown et al., 1999; Liu et al., 2000; Furnari et al., 1999; Lammer et al., 1998; Hofmann et al., 1998; Aguda, 1999; Schmitt et al., 2006) . These molecular events provoke S-phase slowing and G2/M cell-cycle arrest. The importance of p53 in the intra-S phase and G2/M checkpoints is uncertain because most cells lacking p53 retain the ability to slow S-phase progression and to arrest at G2/M after DNA damage O'Connor, 1997; Gupta et al., 1997; Passalaris et al., 1999; Cliby et al., 2002; Flatten et al., 2005) . However, studies have indicated that p53 attenuates the activity of cyclinB1 promoter or promotes the transcriptional activation of the sequestering protein 14-3-3 (Hermeking et al., 1997; Innocente et al., 1999) . Others reported that the p53-regulated GADD45 protein associates with and inhibits cdk1 (cdc2)-cyclinB kinase activity in response to DNA damage (Wang et al., 1999a; Zhan et al., 1999) . Additional regulators of the G2/M checkpoint are the mitotic serine/threonine Polo-like (PLK) and Aurora-like kinases. PLK1 promotes mitotic entry by phosphorylating and activating cdc25C, and in response to DNA damage, PLK1 is inhibited by an ATM-dependent mechanism. Unlike PLK1, PLK3 is involved in the G2/M arrest by phosphorylating and inhibiting cdc25C (Smits et al., 2000; van Vugt et al., 2001; Xie et al., 2001) . AuroraA kinase is normally required for recruitment and activation of cdk1 (cdc2)/cyclinB and commitment of cells into M (Hirota et al., 2003) . In response to DNA damage, inhibition of AuroraA kinase is associated to activation of G2/M checkpoint, whereas its overexpression results in checkpoint bypass (Cazales et al., 2005; Marumoto et al., 2002) .
Although these pathways leading to cell-cycle delay have been identified during the past few years, the dynamic spatio-temporal coordination and regulation of the DNA-damage response network remain poorly understood. Today, a new challenge in cell-cycle checkpoint biology is to understand how cell-cycle checkpoint pathways are coordinated and organized in space and time, to trigger cellular response to DNA damage (Lukas et al., 2004) .
CELLULAR SENESCENCE
Recent investigations in the field of cellular senescence have revealed the importance of DNAdamage responses and cell-cycle checkpoints to initiate cell-cycle arrest associated with cellular senescence. Replicative (or the Hayflick limit) and premature senescence share a common signal, now recognized as DNA strand breaks. In replicative senescence, telomere erosion and shortening yield DNA double-strand breaks at chromosome ends that initiate DNA damage responses (Herbig et al., 2004; d'Adda di Fagagna et al., 2003) . In premature senescence, oncogenic activation leads to elevated intracellular levels of reactive species, augmented numbers of active replicons, alterations in DNA replication fork progression, and the appearance of DNA single-and double-strand breaks that initiate DNA-damage responses (Takahashi et al., 2006; Di Micco et al., 2006; Bartkova et al., 2006; Mallette et al., 2007; Hemann and Narita, 2007) . Similarly, DNA-damaging chemotherapeutic and radiotherapeutic agents provoke DNA replication fork stalling and/or DNA single-and double-strand breaks with activation of the DNAdamage response network (Holliday and Tarrant, 1972; Kung et al., 1990; Di Leonardo et al., 1994; Waldman et al., 1996; Robles and Adami, 1998; Chang et al., 1999a; Suzuki et al., 2001a; Campisi, 2001; Johnstone et al., 2002; Schmitt et al., 2002; Han et al., 2002; Lee and Schmitt, 2003) . Indeed, in models of cellular senescence, ATM/ATR mediate the activation of cell-cycle checkpoints associated with cellular senescence, mainly via p53, CHK1 and CHK2, with the participation of p21, p16 and Rb (reviewed in Schmitt, 2007) . It has been suggested previously that after genotoxic drug treatment, cell-cycle arrest and senescence development are dependent on the p53/p21 pathway in HCT116 colon cancer cells (Han et al., 2002) . Similar observations concerning the importance of the p53/p21 pathway have been reported with other chemotherapeutic agents or irradiation (Di Leonardo et al., 1994; Waldman et al., 1996; Bunz et al., 1998; Linke et al., 1997) . Likewise, studies with bleomycin, actinomycin D and cyclophosphamide have revealed that cells respond to these agents by engaging a p53/p16-dependent long-term senescence program (Robles and Adami, 1998; Schmitt et al., 2002) . However, others have reported senescence phenotypes in p53-mutated cell lines derived from various types of human solid tumors, including cervical, larynx and colon carcinoma, glioma, osteosarcoma (Chang et al., 1999a) and lymphoma cell lines . Typically, senescent cells are observed by flow cytometry after DNA staining as broader G1 or G2/M peaks, and with the appearance of a senescence-associated β-galactosidase activity (pH 6.0).
The DNA-damage responses induced in the early phase of cellular senescence initiation explain how cells will activate cell-cycle checkpoints and undergo cell-cycle arrest at specific phases of the cell cycle. However, after DNA damage, cell-cycle arrests do not always lead to cellular senescence. Indeed, cell-cycle arrests often afford cells the opportunity to repair DNA damage before progressing to the next phase of the cycle. In turn, inappropriate progression of damaged cells through the cell cycle is often associated with mitotic catastrophe, apoptosis and cell death. Thus, the stabilization of cell-cycle arrests to irreversible senescence involves other yet unknown critical events. Recently, epigenetic changes, including histone H3 lysine K9 trimethylation (H3K9) associated with gene silencing, have been suggested as critical mechanisms associated with the stabilization of cell-cycle arrest to cellular senescence, as senescent cells show focal histone H3K9 trimethylation. These foci are now referred to as senescence-associated heterochromatin foci (SAHF) (Schmitt, 2007; Strunnikova et al., 2005; Guney and Sedivy, 2006; Zhang et al., 2007) . Early evidence indicated that H3K9 trimethylation controls DNA methylation in several model organisms (Tamaru and Selker, 2001; Tamaru et al., 2003; Jackson et al., 2002) . Methylation of CpG islands in promoters and locus control regions is strongly associated with H3K9 trimethylation and gene silencing. Indeed, others have indicated that some gene promoters are hypomethylated, whereas others undergo hypermethylation during cellular senescence, suggesting that differential DNA methylation patterns at specific gene promoters and locus control regions may stabilize the senescence phenotype (Tollefsbol and Andrews, 1993; Machwe et al., 2000; Kang et al., 2001; Neumeister et al., 2002; Lopatina et al., 2002; Sun and Arceci, 2005) .
BCL-2 FAMILY MEMBERS AND APOPTOSIS
The Bcl-2 gene was first identified at the chromosomal breakpoint of t(14:18)-bearing B cell lymphomas (Tsujimoto et al., 1984; Cleary et al., 1986) , and was unexpectedly found to act as a new class of oncogenes that function to prevent apoptosis instead of directly promoting cellular proliferation (Hockenbery et al., 1990; Korsmeyer, 1992; McDonnell et al., 1993; Vaux et al., 1988) . Bcl-2 is the founder of a large family of apoptosis regulators that either promote cell survival or facilitate cell death.
The pro-survival members are multidomain proteins that contain BH1, BH2 and BH3 (A1/Bfl-1), BH2 and BH4 (Bcl-xES), and those most similar to Bcl-2 have all 4 BH domains (Bcl-2, Bcl-xL, Mcl-1, Bcl-w, Brag-1, Boo/Diva, Bcl-B/Bcl-2L-10) (Cleary et al., 1986; Boise et al., 1993; Choi et al., 1995; Das et al., 1996; Gibson et al., 1996; Inohara et al., 1998a; Ke et al., 2001; Kozopas et al., 1993; Lin et al., 1993; Schmitt et al., 2004; Song et al., 1999; Zhang et al., 2001 ). According to their structure and biochemical function, the pro-apoptotic members can be further divided into 2 subgroups: multidomain proteins composed of BH domains 1 to 3 (Bax, Bak, Bok/Mtd, Bcl-rambo), BH2 and BH3 (Bcl-gL) or BH4 and BH3 (Bcl-xS) (Boise et al., 1993; Chittenden et al., 1995a; Farrow et al., 1995; Guo et al., 2001; Hsu et al., 1997a; Inohara et al., 1998b; Kataoka et al., 2001; Kiefer et al., 1995; Oltvai et al., 1993) , and BH3-only proteins built of 1 or 2 BH3 domains (Bad, Bid, Bik/Nbk/Blk, Bim/Bod, Hrk/Dp5, Bnip1, Bnip3, Nix, Puma/Bbc3, Noxa, Bcl-gS, Mcl-1s, Map1, Bmf, Spike and ApoL6) (Guo et al., 2001; Bae et al., 2000; Bingle et al., 2000; Boyd et al., 1994; Han et al., 1996; Hegde et al., 1998; Hsu et al., 1998; Imaizumi et al., 1999; Inohara et al., 1997; Matsushima et al., 1998; Nakano and Vousden, 2001; O'Connor et al., 1998; Oda et al., 2000; Puthalakath et al., 2001; Tan et al., 2001; Wang et al., 1996; Yang et al., 1995; Yasuda et al., 1999; Yu et al., 2001; Liu et al., 2005) . In addition to the BH domains, some proteins contain a flexible loop, a pore-forming domain and a transmembrane domain at the carboxy terminal extremity (Adams and Cory, 2001; Chao and Korsmeyer, 1998; Reed, 1997; 1998; Vander Heiden and Thompson, 1999; Zamzami et al., 1998; Cory and Adams, 2002) .
The various Bcl-2 homologues function, at least in part, through protein-protein interactions, forming a complex dynamic network of homo-and heterooligomers, depending on the cellular environment and their subcellular localization. Mutagenesis experiments have suggested that the dimerization potential of Bcl-2-like proteins is greatly influenced by their specific combination of BH domains (Chittenden et al., 1995b; Kelekar and Thompson, 1998; Yin et al., 1994) . Thus, elucidation of the 3-dimensional structure of the anti-apoptotic Bcl-xL has provided a first model in which the α helices located in the BH1, BH2 and BH3 domains create an elongated hydrophobic pocket where a BH3 amphipathic α helice of another Bcl-2-like protein can bind, analogously to a peptide ligand binding to its receptor (Muchmore et al., 1996; Diaz et al., 1997; Sattler et al., 1997) . Heterodimerization between pro-and anti-apoptotic molecules may neutralize one another's activity, suggesting that the relative concentration of one faction versus the other greatly influences the susceptibility of cells to a death signal Sedlak et al., 1995) . Because it provides binding ability, the BH3 motif has become a potent mediator of cell death and is often uniquely required for cell-killing activity (Chittenden et al., 1995b; Polster et al., 2001) . Two distinct models have been proposed to explain the killing activity of the BH3-only proteins (reviewed in Adams and Cory, 2007) . The direct activation model proposes that after a death stimuli, BH3-only proteins promote apoptosis by binding to and inhibiting pro-survival molecules, like Bcl-2, Bcl-xL Bcl-w, Mcl-1 and A1, or by binding to other death agonists, like the multidomain Bax and Bak proteins, which become activated and exert their pro-apoptotic activities at the mitochondrial level. BH3-only proteins that neutralize pro-survival proteins are referred to as BH3 "enabler or sensitizing" proteins, while those that bind pro-apoptotic Bax or Bak are called BH3 "activator or activating" proteins (Chittenden, 2002; Letai et al., 2002; Kuwana et al., 2005; Kim et al., 2006) . The indirect activation model suggests that all BH3-only proteins engage only the pro-survival proteins and act by preventing them from inhibiting Bax or Bak activation Willis et al., 2005; 2007) .
The p53-mediated pathways have been explored extensively in the context of tumor suppression and their response to DNA-damaging agents (Kohn et al., 1994; Hunter and Pines, 1994; Kastan et al., 1995; Kohn, 1996; Kaufmann and Paules, 1996; Jacks, 1996; Tanaka et al., 1996; O'Connor et al., 1997; O'Connor, 1997; Gupta et al., 1997; Passalaris et al., 1999; Hermeking et al., 1997; Innocente et al., 1999; Wang et al., 1999a; Zhan et al., 1999; Johnstone et al., 2002; Levine, 1997; Lowe et al., 1993; Gottlieb and Oren, 1998) . At the level of transcription, multiple p53 target genes, including those of the Bcl-2 family, play crucial roles in promoting apoptosis induced by genotoxic agents. Among them, the Bax gene was one of the first p53-dependent apoptotic targets to be identified (Miyashita and Reed, 1995; Miyashita et al., 1994) ; then, other members of the Bcl-2 family were reported to be p53-downstream targets, such as the BH3-only members Bid (Sax et al., 2002) , Puma (Nakano and Vousden, 2001; Yu et al., 2001; Villunger et al., 2003) and Noxa (Oda et al., 2000; Shibue et al., 2003) . More recently, others have revealed that p53 itself targets mitochondria, where it associates with and activates the multidomain proapoptotic Bax and Bak at the protein level (Chipuk et al., 2004; Leu et al., 2004; Perfettini et al., 2004; Mihara et al., 2003; Dumont et al., 2003; .
Much less is known about the effector genes involved in p53-independent responses after DNA damage. However, most human tumors lose the expression of a functional p53, and they likely represent difficult targets in cancer therapies. Paradoxically, several observations have disclosed that cells lacking the ability to transduce a cell-cycle checkpoint, as a consequence of targeted disruption of p53 or mutated p53, could display hypersensitivity to DNA-damaging treatments, including DNA topoisomerase I and II inhibitors, and undergo apoptosis (Gupta et al., 1997; Waldman et al., 1996; Kaufmann, 1989; 1998; Slichenmyer et al., 1993; Thomas et al., 1996; Bertrand et al., 1991; Solary et al., 1992; Dubrez et al., 1995; Shimizu and Pommier, 1997; Kaufmann and Earnshaw, 2000; Droin et al., 1998) . p73 and p63, other p53 family members that can be activated when cells are damaged, also contribute to programmed cell death induction, in the presence or absence of p53 after DNA damage (Jost et al., 1997; Yang et al., 1998; Yuan et al., 1999; Gong et al., 1999; Agami et al., 1999; Costanzo et al., 2002; Flores et al., 2002; Bergamaschi et al., 2003; Freebern et al., 2003; Nozell et al., 2003) . While the p73 and p63 functional domains necessary for mediating apoptosis have been characterized, much less is known about the p73 or p63 target genes of Bcl-2 family members (Jost et al., 1997; Yang et al., 1998; Yuan et al., 1999; Gong et al., 1999; Agami et al., 1999; Costanzo et al., 2002; Flores et al., 2002; Bergamaschi et al., 2003; Freebern et al., 2003; Nozell et al., 2003; Fontemaggi et al., 2002) . Recently, Melino et al.(2004) reported that p73 isoform overexpression can directly induce Puma transactivation.
E2F1 transcription factor has been shown to participate in the induction of apoptosis in the presence or absence of p53 (Hunt et al., 1997; Phillips et al., 1997; Holmberg et al., 1998) . Overexpression of E2F1 itself can directly activate p73 transcription (Stiewe and Pützer, 2000) and regulate the expression of several genes involved in apoptosis, including the multi-domain pro-apoptotic Bak, the BH3-only proteins Bid, Bad, Bim, Noxa, Puma, Hrk, the adaptor protein Apaf-1 and caspase-3 and -7 (Muller et al., 2001; Stanelle et al., 2002; Pediconi et al., 2003; Hershko and Ginsberg, 2004) . Some of these targeted genes are also regulated by E2F1 following cisplatin or doxorubicin treatment of p53-deficient mouse embryo fibroblasts (Hershko and Ginsberg, 2004) , highlighting its importance for drug responses. NFκB activation after DNA topoisomerase inhibitor treatment was shown to be p53-independent (Piret et al., 1999) , but reported to be essential in p53-mediated cell death induced by DNA damage, highlighting its important role (Ryan et al., 2000) . Activation of NFκB and c-Jun/Ap-1 contributes either to protect cells from death or activates cell death, depending on the cellular environment (Foo and Nolan, 1999; Mercurio and Manning, 1999; Grumont et al., 1998) , and a growing number of genes related to apoptosis have been demonstrated to be induced by NFκB and c-Jun/Ap-1 in response to multiple stress-inducing agents, including DNA damage (Chu et al., 1997; Stehlik et al., 1998; Wang et al., 1998; Tamatani et al., 1999; Zong et al., 1999; Stroka et al., 1999) .
Bcl-2 family members generally localize to separate subcellular compartments in the absence of a death signal. Anti-apoptotic members, like Bcl-2 and Bcl-xL, usually reside on the cytoplasmic face of the outer mitochondrial membrane (OMM), endoplasmic reticulum and nuclear envelope (Hockenbery et al., 1990; Krajewski et al., 1993; Zamzami et al., 1996) . In contrast, death-inducing members, such as Bax, Bad and Bid, are rather free in unstimulated cells, except for the multidomain Bak which seems to constitutively reside in the OMM (Gross et al., 1998; Korsmeyer et al., 2000; Hsu et al., 1997b) . In turn, the BH3-only Bim and Bmf are linked to cytoskeleton components via binding to the large microtubular dynein motor complex and myosin V actin motor complex, respectively (Puthalakath et al., 1999; . After a death signal, multidomain pro-apoptotic proteins, like Bax, undergo a conformational change which gives them the capacity to target and insert into intracellular membranes, especially in the mitochondria. The transmembrane domain appears to be important in conferring membrane-docking capacity to both pro-and anti-apoptotic members as well as in providing protein stability, even though reports indicate that deletion of this domain does not abrogate the function of most Bcl-2-like proteins (Borner et al., 1994; Nguyen et al., 1994) .
Regulation of mitochondrial membrane permeabilization is the major means by which Bcl-2-like proteins exert their apoptosis regulatory effect. As a site of convergence for multiple death-inducing stimuli, the mitochondria are a pivotal decision centre that controls life and death by releasing apoptogenic factors in the cytosol. These death-inducing molecules are located within the mitochondrial intermembrane space and include cytochrome c (Kluck et al., 1997; Yang et al., 1997) , DIABLO/Smac, a factor that promotes caspase activation by its effect on IAPs (inhibitor of apoptosis proteins) (Du et al., 2000; Verhagen et al., 2000) , the nuclease activator AIF (apoptosis-inducing factor) , Endo G (an apoptotic DNase) Parrish et al., 2001 ), HtrA2/Omni (an inhibitor of IAPs that also contains pro-apoptotic serine protease activity) (Suzuki et al., 2001b) , and some pro-caspases (Krajewski et al., 1999; Mancini et al., 1998; Qin et al., 2001; Susin et al., 1999b) . Permeabilization of the OMM is usually followed by caspase-9 activation and irreversible apoptosis. Bcl-2 family members may control the mitochondrial permeabilization phase (Desagher and Martinou, 2000) via 3 prevailing models: first, by forming autonomous channels in the OMM; second, by interfering with mitochondrial permeability transition pores (mPTP); and, finally, by promoting dynamic alterations in the structure of the lipid bilayer (Gross et al., 1998; Kluck et al., 1997; Yang et al., 1997; Antonsson et al., 1997; Minn et al., 1997; Chou et al., 1999; McDonnell et al., 1999; Schendel et al., 1998; Schlesinger et al., 1997; Bossy-Wetzel et al., 1998; Vander Heiden et al., 1997; Saito et al., 2000; Pavlov et al., 2001; Basañez et al., 1999; Kudla et al., 2000; Epand et al., 2002; Kuwana et al., 2002) . Anti-apoptotic proteins seem to exert their function in part by inhibiting the formation of death-inducing pores by pro-apoptotic proteins, and a study has reported that the Bcl-2 channel could potentially inhibit apoptosis by evoking H + efflux from the mitochondria, preserving mitochondrial transmembrane potential (∆Ψ m ) (Shimizu et al., 1998) . Anti-apoptotic proteins may also protect cells from death by inhibiting the production of reactive oxygen species (Hockenbery et al., 1993; Kane et al., 1993) , by preventing intracellular acidification (Gottlieb et al., 1996) , by increasing mitochondrial Ca 2+ capacity Shimizu et al., 1998) , and by providing overall stabilization of the membrane into which they are inserted (Vander Heiden et al., 1997; Zamzami et al., 1995) . These pro-survival mechanisms are not well defined and may or may not involve the pore-forming capacity of anti-apoptotic proteins. In the first model, Bcl-2-like proteins modulate OMM permeabilization without altering mitochondrial function, which means that ∆Ψ m is maintained as well as ATP production. This is crucial because in the absence of dATP or ATP, the apoptosome cannot form, caspase-9 is not activated, and the cells tend to die by necrosis rather than by apoptosis (Chautan et al., 1999; Nicotera et al., 1999) . The second model of OMM permeabilization involves mPTP, or megachannels, which form at contact sites between the outer and inner mitochondrial membranes Zoratti and Szabo, 1995) . Its core components are the voltage-dependent anion channel 1 (VDAC1), the adenine nucleotide translocator (ANT), the peripheral benzodiazepine receptor, the mitochondrial matrix cyclophilin as well as hexokinase and creatine kinase, which all create a large conductance pore permeable to solute with a molecular mass of ≤1.5 kDa (Bernardi et al., 1999; Crompton, 1999) . mPTP opening results in mitochondrial depolarization and the subsequent dissipation of ∆Ψ m , uncoupling of oxidative phosphorylation, and swelling of the mitochondrial matrix (Bernardi et al., 1999) . OMM rupture may eventually occur as a consequence of matrix expansion, releasing the intermembrane space contents (cytochrome c, DIABLO/Smac, Omni/HtrA2, AIF) into the cytosol in a nonspecific manner (Harris and Thompson, 2000; Zamzami and Kroemer, 2001) . Interactions between some members of the Bcl-2 family and the components of mPTP have been proposed by several studies. Pro-apoptotic molecules like Bax could bind to ANT and promote mPTP opening, an effect prevented by the anti-apoptotic Bcl-2 . The multidomains Bax and Bak could also interact with the VDAC1, enhancing its channel activity to allow passage of cytochrome c, while the BH4 domain of anti-apoptotic Bcl-2 and Bcl-xL rather stimulates closure of the channel (Shimizu et al., 1999; . Recently, Sugiyama et al.(2002) have shown that the BH3-only Bim, but not Bid, may also interact with the VDAC1 and promote its opening, which results in loss of ∆Ψ m and cytochrome c release. By interacting with mPTP, pro-apoptotic proteins thus appear to be capable of enhancing the basal permeability of mPTP, allowing molecules larger than 1.5 kDa to diffuse through.
BCL-2 FAMILY MEMBERS AND CELL-CYCLE CHECKPOINTS
In addition to their central role in controlling cell death, numerous studies have linked some Bcl-2-like family members with cell cycle progression (summarized in Fig.1 ). First, Bcl-2 itself was shown to slow entry from the quiescent G0 into the G1 phase of the cell cycle prior to DNA replication in multiple cell lineages and transgenic mice (Fig.1) . In contrast, Bcl-2 −/− knockout cells enter the S phase more quickly (Borner, 1996; Brady et al., 1996; Vairo et al., 1996; Mazel et al., 1996; Linette et al., 1996; O'Reilly et al., 1996; Huang et al., 1997; Knowlton et al., 1998; Ogilvy et al., 1999; Gillardon et al., 1999; Domen et al., 2000; Vail et al., 2002) . This effect of Bcl-2 on cell proliferation is genetically distinct from its function on apoptosis (Borner, 1996; Brady et al., 1996; Vairo et al., 1996; Huang et al., 1997; Knowlton et al., 1998) . Mutation of a tyrosine residue (Tyr28) within the BH4 domain has no impact on the ability of Bcl-2 to inhibit apoptosis and does not prevent its heterodimerization with death-inducing family members, including Bax, Bak, Bad, and Bik. However, when starved quiescent cells expressing the mutated protein are stimulated by serum, they re-enter the cell cycle faster than those expressing wild-type Bcl-2 protein (Huang et al., 1997) .
Mcl-1, another Bcl-2 homologue known to function as an anti-apoptotic protein (Kozopas et al., 1993) , inhibits cell-cycle progression through the S phase of the cell cycle (Fig.1) . The cell-cycle regulatory function of Mcl-1 is partially mediated through its interaction with proliferating cell nuclear antigen (PCNA), a cell cycle regulator that plays a critical role in DNA replication (Fujise et al., 2000) . The binding motif for PCNA resides between the 221st to 228th amino acids of Mcl-1. Mutations introduced within this region do not alter the anti-apoptotic function of Mcl-1, but impede its binding to PCNA and significantly reduce its effect on cell cycle progression (Fujise et al., 2000) . Thus, this effect of Mcl-1 on cell proliferation is genetically distinct from its function on apoptosis. More recently, others have revealed that a proteolytic fragment of Mcl-1 regulates cell growth via interaction with cdk1 (cdc2) (Jamil et al., 2005) .
Microtubule inhibitors widely used in cancer chemotherapy, including paclitaxel, taxotere, vinblastine and vincristine, induce mitotic arrest linked with Bcl-2, Bcl-xL and Mcl-1 phosphorylation (Haldar et al., 1995; Blagosklonny et al., 1997; Poruchynsky et al., 1998; Domina et al., 2000) . However, studies have revealed that Bcl-2 and Bcl-xL phosphorylation is tightly coupled with normal mitotic events (Domina et al., 2000; Ling et al., 1998; Scatena et al., 1998; Fan et al., 2000a) . Bcl-2 phosphorylation multisites (Ser70, Ser87, Thr69) are located within the unstructured loop domain of the protein, a region not essential for its anti-apoptotic function Haldar et al., 1998; Fang et al., 1998; Srivastava et al., 1999; Yamamoto et al., 1999) . Multiple kinases have been proposed to phosphorylate Bcl-2 (and presumely Bcl-xL), including an Ask1/Jun-N-terminal protein kinase 1 pathway, normally activated at G2/M (Fan et al., 2000a; 2000b; Yamamoto et al., 1999; Blagosklonny et al., 1996; Ruvolo et al., 1998; Srivastava et al., 1998; Maundrell et al., 1997; Kharbanda et al., 2000) .
In addition, Kharbanda et al.(2000) have reported that Bcl-xL is phosphorylated on Thr47, within the unstructured loop domain, and on Thr115, adjacent to the α3 helix of Bcl-xL, in response to ionizing radiation.
Recent works have also indicated a role for Bid in the intra-S phase checkpoint after replicative stress in response to DNA-damaging agents (Fig.1) . This role of Bid is mediated through its phosphorylation at Ser78 and Ser61/64, by the DNA-damage kinase ATM (Zinkel et al., 2005; Kamer et al., 2005) . More recently, we showed that in addition to its mitochondrial effect that delays apoptosis, Bcl-xL co-localizes and binds to cdk1 (cdc2) during the G2/M cell-cycle checkpoint, and its overexpression stabilizes a G2/M-arrest senescence program in surviving cells after DNA damage (Fig.1) . Bcl-xL potently inhibits cdk1 (cdc2) kinase activities, which is reversible by a synthetic peptide between the 41st to 60th amino acids surrounding the Thr47 and Ser62 phosphorylation sites, and Asn52 deamidation site, within the flexible loop domain of Bcl-xL. A mutant deleted of this region does not alter the anti-apoptotic function of Bcl-xL, but impedes its effect on cdk1 (cdc2) activities and on the G2/M-arrest senescence program after DNA damage. The nuclear interaction of Bcl-xL and cdk1 (cdc2) suggests that Bcl-xL is coupled to the stabilization of a cell-cycle checkpoint induced by DNA damage, and this effect is genetically distinct from its function on apoptosis .
CONCLUSION
Recent progress in understanding the molecular mechanisms of DNA-damage response illustrates how the key components interplay into different processes to protect genomic integrity of cells. Already, strong efforts are being made by several laboratories to develop new compounds targeting cell-cycle progression, cell-cycle checkpoint and apoptosis regulatory proteins. Several natural products and synthetic chemicals occupied the BH3-binding site of anti-apoptotic Bcl-2 family members and some of these compounds promote apoptosis of tumor cells (summarized in Table 1 ) (reviewed in Reed, 2006) . Knowing more about the molecular interdependence of the DNA-damage response network will certainly be helpful in designing rational therapeutic protocols
Bcl-xL with these new compounds in combination with traditional chemotherapy. Insights into the dynamic nature of these processes and the spatio-temporal orchestration of their regulation will suggest novel potential therapeutic strategies to prevent and treat cancer in the near future.
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